Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

Abramson Cancer Center at Penn Medicine

Status and phase

Completed

Phase 2

Conditions

Stage IV Squamous Cell Carcinoma of the Hypopharynx

Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Stage IV Verrucous Carcinoma of the Larynx

Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Stage IV Salivary Gland Cancer

Recurrent Squamous Cell Carcinoma of the Hypopharynx

Stage IV Verrucous Carcinoma of the Oral Cavity

Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity

Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity

Stage IV Squamous Cell Carcinoma of the Oropharynx

Recurrent Squamous Cell Carcinoma of the Larynx

Recurrent Metastatic Squamous Neck Cancer With Occult Primary

Recurrent Verrucous Carcinoma of the Larynx

Salivary Gland Squamous Cell Carcinoma

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma

Stage IV Squamous Cell Carcinoma of the Larynx

Recurrent Verrucous Carcinoma of the Oral Cavity

Head and Neck Cancer

Recurrent Squamous Cell Carcinoma of the Oropharynx

Recurrent Salivary Gland Cancer

Treatments

Drug: capecitabine

Drug: lapatinib ditosylate

Study type

Interventional

Funder types

Other

Identifiers

NCT01044433

UPCC 15309

NCI-2009-01492

Details and patient eligibility

About

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving capecitabine together with lapatinib ditosylate may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving capecitabine and lapatinib ditosylate together works in treating patients with squamous cell cancer of the head and neck.

Full description

PRIMARY OBJECTIVE:

I. Overall survival (OS) will be the primary endpoint.

SECONDARY OBJECTIVES:

I. Progression free survival (PFS). II. Time to disease progression and sites of progression. III. Response rate. IV. Toxicity of the combination in this population. V. Quality of life.

OUTLINE:

Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for up to 5 years.

Enrollment

44 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion

Histologically or cytologically confirmed SCCHN
All primary sites are eligible excluding nasopharyngeal
Metastatic disease or locally recurrent disease not felt amenable to curative therapy (as determined by a physician)
ECOG performance status 0-2
No prior chemotherapy in the metastatic / locally advanced, recurrent incurable setting; patients may have received prior curative-intention chemotherapy including induction chemotherapy, chemotherapy concurrent with radiation and adjuvant chemotherapy
No prior capecitabine; patients who have received 5-FU or other fluoropyrimidines in the curative-intention setting will not be excluded, as long as more than 6 mos have elapsed since prior 5-FU exposure
No previous history of Lapatinib
Previous use of cetuximab in the curative-intention setting will not result in exclusion, as long as at least four weeks have elapsed since prior C225 exposure
Patients may have received radiation therapy in the definitive, adjuvant or metastatic setting; radiation therapy must be completed at least 14 days prior to study participation
ECOG performance status of 0-2 (Karnofsky >= 60%)
Must have normal organ and marrow function
Laboratory tests should be completed within 14 days prior to registration
Left ventricular ejection fraction (LVEF) can be determined by either echocardiography or nuclear scintigraphy and should be obtained within 21 days of enrollment
Platelets >= 100,000/mm^3
Total bilirubin =< 2
Albumin > 2.5
AST(SGOT)/ALT(SGPT) =< 5.0 X institutional upper limit of normal (for patients with hepatic metastases) =< 3.0 X institutional upper limit of normal (for patients without hepatic metastases)
GFR > 30 (by standard Cockroft and Gault formula)
LVEF >= 50%
Patients may receive anticoagulant medication while on study
Patients may not receive other antineoplastic therapies such as chemotherapy or radiation treatments while on study; patients may not receive other experimental treatments while on study; patients requiring radiation treatments during protocol-based treatment will be taken off study
Patients may receive concurrent bisphosphonate therapy as well as hormonal manipulations for appetite while on study
Patients must neither be pregnant nor expect to become pregnant while on study
Patients must have the ability to understand and the willingness to sign a written informed consent document
Adequate swallowing function or gastric-tube for drug administration
No disability with absorption of internal medications
Adequate nutritional status: Patients will not be excluded based on previous weight loss but will be required to have adequate nutrition at the time of study entry as measured by serum albumin
ANC >= 1,500/mm^3
Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation

Exclusion

Patients who have received prior capecitabine chemotherapy or lapatinib
Patients with brain metastases may participate if they have undergone appropriate treatment for the lesion(s), are at least two weeks post treatment without evidence for post-treatment progression, have no significant neurologic symptoms, and are no longer on steroids for brain metastases
Patients with symptoms concerning for CNS metastases should be evaluated with imaging prior to study participation
Less than 3 weeks elapsed since prior exposure to chemotherapy
LVEF < 50% or symptomatic congestive heart failure (CHF)
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women are excluded due to the potential for teratogenic or abortifacient effects of capecitabine and lapatinib; because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued prior to participation of the mother on study
Other active, invasive malignancy requiring ongoing therapy or expected to require systemic therapy within two years; localized squamous cell carcinoma of the skin, basal-cell carcinoma of the skin, carcinoma in-situ of the cervix, or other malignancies requiring locally ablative therapy only will not result in exclusion
Have received treatment within the last 30 days prior to study entry with any drug that has not received regulatory approval for an indication at the time of study entry
Previous CHF or other cardiac conditions shall not result in exclusion if the treating physician does not see contraindication to these medications; if contraindication is controversial, cardiac consultation will be obtained prior to the initiation of therapy
Anti-cancer therapy (other than the investigational regimen) is prohibited from 3 weeks before the first dose of investigational product through discontinuation unless otherwise noted
Investigational drugs are not permitted from 3 weeks (21 days) or 5 half-lives, whichever is longer, prior to the first dose and up through 30 days after the last dose of investigational product
CYP3A4 inducers and inhibitors, antacids, and herbal or dietary supplements
Concurrent radiation therapy and surgery for SCCHN is prohibited during therapy